---
document_datetime: 2024-01-17 16:03:16
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tegsedi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: tegsedi-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.7636052
conversion_datetime: 2025-12-26 20:55:46.129361
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tegsedi

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------|
| IB/0040              | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                  | 13/12/2023                          | n/a                                         |                                  |                                                                        |
| II/0038              | Update of sections 4.4 and 4.8 of the SmPC in order to modify the warning on liver monitoring and drug- induced liver injury and to add 'drug-induced liver | 30/11/2023                          |                                             | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Tegsedi-H-C-004782- II-Var.38'. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | injury' to the list of adverse drug reactions (ADRs) with frequency not known, following the request in the Assessment Report for PAM procedure EMEA/H/C/004782/LEG/008. The Annex II and Package Leaflet are updated accordingly. The RMP version 4.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor updates to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |             | Amendments to the SmPC to modify the warning on liver monitoring and drug-induced liver injury and to add 'drug- induced liver injury' to the list of adverse drug reactions. Update of the risk management plan to include Hepatotoxicity as a new important identified risk. Additional Risk Minimization Measures (patient alert cards) are also updated accordingly. The Annex II and Package Leaflet are also updated and in addition, the MAH took the opportunity to introduce minor updates to the PI. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0037           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                  | 10/07/2023 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/10697 /202207 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/02/2023 | 19/04/2023 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10697/202207.                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0035              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                             | 26/01/2023 | 24/03/2023 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Tegsedi in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                                                                                                                          |
| II/0034             | Submission of the final report from study ISIS 420915-CS3, listed as a category 3 in the RMP. This is an Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP).                                                                                                                                                                                                                              | 09/03/2023 | n/a        |             | Submission of the final report from Open-Label Extension Study to Assess the Long-Term Safety and Efficacy in Patients with Familial Amyloid Polyneuropathy (FAP).                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |           |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| IAIN/0036 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/11/2022 | 24/03/2023 | SmPC, Labelling and PL |           |
| IB/0031   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 15/10/2022 | 24/03/2023 | Annex II               |           |
| IA/0033/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test | 19/09/2022 | n/a        |                        | procedure |
| IA/0030   | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 22/08/2022 | n/a        |                        |           |

<div style=\"page-break-after: always\"></div>

|           | product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------|
| IA/0029/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or excipient | 08/08/2022 | n/a        |      | manufacturer of a novel  |
| IB/0028   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 28/07/2022 | 21/09/2022 | SmPC |                          |
| IB/0027   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 27/07/2022 | n/a        |      |                          |
| II/0026   | Updated RMP version 3.1 removes carcinogenicity in rats as missing information, adds a targeted pharmacovigilance measure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 10/03/2022 | n/a        |      | questionnaire as routine |

<div style=\"page-break-after: always\"></div>

|                     | and a patient alert card as additional risk minimisation for liver transplant rejection. Adds 'injection site reactions' and 'immunogenicity' as risks not considered important for inclusion in the summary of safety concerns (SVII.1.) and updates the patient alert card with additional warnings on hepatic monitoring and ocular toxicity. Further sections of the RMP are updated. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |                                  |                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10697 /202107 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 10/02/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                          |
| PSUSA/10697 /202101 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/09/2021 | 09/11/2021 | SmPC                             | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10697/202101. |
| IB/0024             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15/10/2021 | 21/09/2022 | SmPC, Annex II, Labelling and PL |                                                                                                                                            |
| IB/0023             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 19/07/2021 | 09/11/2021 | SmPC, Labelling and PL           | To extend the shelf life from 36 months to 48 months when stored at 2°-8°C and protected from light.                                       |
| IB/0022             | B.II.z - Quality change - Finished product - Other                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/06/2021 | n/a        |                                  |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | variation                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10697 /202007 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                              | 25/02/2021 | 21/04/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10697/202007. |
| IB/0019             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                        | 19/03/2021 | n/a        |             |                                                                                                                                            |
| IA/0020             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                        | 05/03/2021 | n/a        |             |                                                                                                                                            |
| IB/0018             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                               | 07/12/2020 | n/a        |             |                                                                                                                                            |
| IA/0017             | B.II.f.1.e - Stability of FP - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                              | 27/11/2020 | n/a        |             |                                                                                                                                            |
| IAIN/0016/G         | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 16/10/2020 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |             |                                                                                                                                                                                                                                                                                                                                                         |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10697 /202001 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 03/09/2020 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                       |
| II/0011             | Update of SmPC section 5.3 to reflect the results of rat carcinogenicity study. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                      | 03/09/2020 | 03/11/2020 | SmPC and PL | The final report of a 2-year subcutaneous (s.c.) carcinogenicity study of ISIS 420915 has shown dose- related incidence of subcutaneous pleomorphic fibrosarcoma and subcutaneous fibrosarcoma (monomorphic type) at 2 and 6 mg/kg/week in the injection site or injection site regions. The human relevance of these findings is considered to be low. |
| IB/0014             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                          | 14/05/2020 | 03/11/2020 | SmPC        |                                                                                                                                                                                                                                                                                                                                                         |
| IB/0013/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 22/04/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |                       |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------|
| PSUSA/10697 /201907 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/01/2020 | n/a        |                       | PRAC Recommendation - maintenance |
| IAIN/0010/G         | This was an application for a group of variations. A.6 - Administrative change - Change in ATC Code/ATC Vet Code B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 22/11/2019 | 03/11/2020 | SmPC, Annex II and PL |                                   |
| IB/0009/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/10/2019 | n/a        |                       |                                   |

<div style=\"page-break-after: always\"></div>

|                     | the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size                                                                                                                                            |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10697 /201901 | Periodic Safety Update EU Single assessment - inotersen                                                                                                                                                                                                                                                                                                              | 25/07/2019 | 19/09/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10697/201901. |
| IB/0007             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                                                                                                  | 31/07/2019 | n/a        |             |                                                                                                                                            |
| IA/0006/G           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 14/06/2019 | n/a        |             |                                                                                                                                            |
| IB/0005             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                            | 10/05/2019 | 19/09/2019 | SmPC        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| T/0003   | Transfer of Marketing Authorisation                                                                         | 01/02/2019   | 01/03/2019   | SmPC, Labelling and PL   |
|----------|-------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| IB/0002  | B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation | 26/11/2018   | n/a          |                          |
| T/0001   | Transfer of Marketing Authorisation                                                                         | 28/08/2018   | 12/09/2018   | SmPC, Labelling and PL   |